Jane Orr is Managing Director of Mundipharma Australia, but she is also a pharmacist, which gives her a unique perspective on community pharmacy. Although Mundipharma has traditionally had a strong prescription-medicines portfolio, it has recently diversified its business by investing in consumer health. The company...
Singapore, 3rd December, 2015: Mundipharma Ophthalmology Products Limited today announced an agreement with MSD, known as Merck in the United States and Canada, to acquire MSD’s ophthalmology portfolio for the treatment of increased ocular pressure caused by open angle glaucoma or ocular hypertension, in Australia,...
Mundipharma has once again received an industry award for its supply of prescription medicines. Last night in Melbourne, Mundipharma was recognised when winning the Sigma “Specialised Ethical Supplier of the Year” Award. Other Nominees included Amgen and Novo Nordisk. Robert Ingui, Finance and Operations director at Mundipharma...
Mundipharma ran its 100th Pain Management Master Classes in November 2015, with the program servicing over 4,500 healthcare practitioners all around Australia since it began. The Pain Management Master Classes were launched in 2009 as part of the CARE by mundipharma® offering (Clinical Academic Resources &...
Starting Friday 9 October, Mundipharma launched a month long cross media campaign on radio, newspapers and websites to prompt patients suffering constipation related to their pain medication to discuss the issue with their GP. The Sydney focused cross media campaign is a major initiative for...
Mundipharma Pty Limited launched their first Australian consumer campaign for Burnaid® in an effort to raise awareness of the brand and of how to treat burns adequately. Research* showed that 88% of burns happen at home, mostly in the kitchen, and people are using ice, butter or even toothpaste...
Purdue Pharma L.P. and AnaBios Corporation announced today the intent to form a joint venture aimed at accelerating the development of Purdue Pharma’s Nav1.7 sodium ion channel compounds for the treatment of chronic pain. The joint research and development effort would leverage Purdue Pharma’s intellectual...
Purdue Pharma L.P. announced today the acquisition from VM Pharma LLC of VM-902A, a first-in-class, allosteric selective tropomyosin receptor kinase A (TrkA) inhibitor, as well as the backup compounds and associated intellectual property for the potential treatment of chronic pain. TrkA is a member of...
Mundipharma and Burnaid® recently made a significant donation to the Ravenshoe Café Explosion Response Fund created by the Julian Burton Burns Trust. The explosion at this Queensland café resulted in significant burn injuries in several people as well as two deaths. The Julian Burton Burns Trust...
Mundipharma Laboratories GmbH and its independent associated company, Purdue Pharmaceuticals LP, today announced that they have entered into a global multi programme discovery and development collaboration with Laboratorios Esteve, S.A. to bring to market important next generation products for the management of pain. Under the...